Four years hence, Ascendis Pharma A/S is forecast to have the bestselling therapy for hypoparathyroidism. But AstraZeneca PLC clearly believes it can muscle in, having today bought Amolyt Pharma for $800m upfront.
AstraZeneca Spends $800m On Amolyt And Awaits A Readout
The Phase III trial of hypoparathyroidism asset eneboparatide will have to hit if AstraZeneca is going to carve out market share from Ascendis.
